Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: Multiple blood markers profiling study

So Young Park, Jinkwon Kim, Ok Joon Kim, Jin Kyeoung Kim, Jihwan Song, Dong Ah Shin, Seung Hun Oh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: There is no single blood marker for predicting the prognosis in ischemic stroke. A combination of multiple blood markers may enhance the ability to predict long-term outcome following ischemic stroke.Methods: Blood concentrations of neuronal markers (neuron-specific enolase, visinin-like protein 1, heart type fatty acid binding protein (hFABP) and neuroglobin), astroglial markers (S100B and glial fibrillary acidic protein), inflammatory markers (IL-6, TNF-α, and C-reactive protein), blood-brain barrier marker (matrix metalloproteinase 9), and haemostatic markers (D-dimer and PAI-1) were measured within 24 hours after stroke onset. The discrimination and reclassification for favorable and poor outcome were compared after adding individual or a combination of blood markers to the clinical model of stroke outcome.Results: In multivariate analysis, natural log-transformed (log) IL-6 (odds ratio (OR): 1.75, 95% CI: 1.25 to 2.25, P = 0.001) and loghFABP (OR: 3.23, 95% CI: 1.44 to 7.27, P = 0.005) were independently associated with poor outcome. The addition of a single blood marker to the clinical model did not improve the discriminating ability of the clinical model of stroke outcome. However, the addition of the combination of logIL-6 and loghFABP to the clinical model showed improved discrimination (area under receiver operating characteristic (AUROC) curve: 0.939 versus 0.910, P = 0.03) and reclassification performance (net reclassification improvement index: 0.18, P = 0.005).Conclusions: A combination of circulating IL-6 and hFABP level has an additive clinical value for the prediction of stroke outcome.

Original languageEnglish
Article numberR45
JournalCritical Care
Volume17
Issue number2
DOIs
Publication statusPublished - 2013 Mar 16

Fingerprint

Fatty Acid-Binding Proteins
Cerebral Infarction
Interleukin-6
Stroke
Neurocalcin
Biomarkers
Odds Ratio
Phosphopyruvate Hydratase
Glial Fibrillary Acidic Protein
Plasminogen Activator Inhibitor 1
Matrix Metalloproteinase 9
Hemostatics
Blood-Brain Barrier
ROC Curve
C-Reactive Protein
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

@article{851d4628a0e14ffb9254f8c85124ecb5,
title = "Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: Multiple blood markers profiling study",
abstract = "Introduction: There is no single blood marker for predicting the prognosis in ischemic stroke. A combination of multiple blood markers may enhance the ability to predict long-term outcome following ischemic stroke.Methods: Blood concentrations of neuronal markers (neuron-specific enolase, visinin-like protein 1, heart type fatty acid binding protein (hFABP) and neuroglobin), astroglial markers (S100B and glial fibrillary acidic protein), inflammatory markers (IL-6, TNF-α, and C-reactive protein), blood-brain barrier marker (matrix metalloproteinase 9), and haemostatic markers (D-dimer and PAI-1) were measured within 24 hours after stroke onset. The discrimination and reclassification for favorable and poor outcome were compared after adding individual or a combination of blood markers to the clinical model of stroke outcome.Results: In multivariate analysis, natural log-transformed (log) IL-6 (odds ratio (OR): 1.75, 95{\%} CI: 1.25 to 2.25, P = 0.001) and loghFABP (OR: 3.23, 95{\%} CI: 1.44 to 7.27, P = 0.005) were independently associated with poor outcome. The addition of a single blood marker to the clinical model did not improve the discriminating ability of the clinical model of stroke outcome. However, the addition of the combination of logIL-6 and loghFABP to the clinical model showed improved discrimination (area under receiver operating characteristic (AUROC) curve: 0.939 versus 0.910, P = 0.03) and reclassification performance (net reclassification improvement index: 0.18, P = 0.005).Conclusions: A combination of circulating IL-6 and hFABP level has an additive clinical value for the prediction of stroke outcome.",
author = "Park, {So Young} and Jinkwon Kim and Kim, {Ok Joon} and Kim, {Jin Kyeoung} and Jihwan Song and Shin, {Dong Ah} and Oh, {Seung Hun}",
year = "2013",
month = "3",
day = "16",
doi = "10.1186/cc12564",
language = "English",
volume = "17",
journal = "Critical Care",
issn = "1466-609X",
publisher = "BioMed Central Ltd.",
number = "2",

}

Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction : Multiple blood markers profiling study. / Park, So Young; Kim, Jinkwon; Kim, Ok Joon; Kim, Jin Kyeoung; Song, Jihwan; Shin, Dong Ah; Oh, Seung Hun.

In: Critical Care, Vol. 17, No. 2, R45, 16.03.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction

T2 - Multiple blood markers profiling study

AU - Park, So Young

AU - Kim, Jinkwon

AU - Kim, Ok Joon

AU - Kim, Jin Kyeoung

AU - Song, Jihwan

AU - Shin, Dong Ah

AU - Oh, Seung Hun

PY - 2013/3/16

Y1 - 2013/3/16

N2 - Introduction: There is no single blood marker for predicting the prognosis in ischemic stroke. A combination of multiple blood markers may enhance the ability to predict long-term outcome following ischemic stroke.Methods: Blood concentrations of neuronal markers (neuron-specific enolase, visinin-like protein 1, heart type fatty acid binding protein (hFABP) and neuroglobin), astroglial markers (S100B and glial fibrillary acidic protein), inflammatory markers (IL-6, TNF-α, and C-reactive protein), blood-brain barrier marker (matrix metalloproteinase 9), and haemostatic markers (D-dimer and PAI-1) were measured within 24 hours after stroke onset. The discrimination and reclassification for favorable and poor outcome were compared after adding individual or a combination of blood markers to the clinical model of stroke outcome.Results: In multivariate analysis, natural log-transformed (log) IL-6 (odds ratio (OR): 1.75, 95% CI: 1.25 to 2.25, P = 0.001) and loghFABP (OR: 3.23, 95% CI: 1.44 to 7.27, P = 0.005) were independently associated with poor outcome. The addition of a single blood marker to the clinical model did not improve the discriminating ability of the clinical model of stroke outcome. However, the addition of the combination of logIL-6 and loghFABP to the clinical model showed improved discrimination (area under receiver operating characteristic (AUROC) curve: 0.939 versus 0.910, P = 0.03) and reclassification performance (net reclassification improvement index: 0.18, P = 0.005).Conclusions: A combination of circulating IL-6 and hFABP level has an additive clinical value for the prediction of stroke outcome.

AB - Introduction: There is no single blood marker for predicting the prognosis in ischemic stroke. A combination of multiple blood markers may enhance the ability to predict long-term outcome following ischemic stroke.Methods: Blood concentrations of neuronal markers (neuron-specific enolase, visinin-like protein 1, heart type fatty acid binding protein (hFABP) and neuroglobin), astroglial markers (S100B and glial fibrillary acidic protein), inflammatory markers (IL-6, TNF-α, and C-reactive protein), blood-brain barrier marker (matrix metalloproteinase 9), and haemostatic markers (D-dimer and PAI-1) were measured within 24 hours after stroke onset. The discrimination and reclassification for favorable and poor outcome were compared after adding individual or a combination of blood markers to the clinical model of stroke outcome.Results: In multivariate analysis, natural log-transformed (log) IL-6 (odds ratio (OR): 1.75, 95% CI: 1.25 to 2.25, P = 0.001) and loghFABP (OR: 3.23, 95% CI: 1.44 to 7.27, P = 0.005) were independently associated with poor outcome. The addition of a single blood marker to the clinical model did not improve the discriminating ability of the clinical model of stroke outcome. However, the addition of the combination of logIL-6 and loghFABP to the clinical model showed improved discrimination (area under receiver operating characteristic (AUROC) curve: 0.939 versus 0.910, P = 0.03) and reclassification performance (net reclassification improvement index: 0.18, P = 0.005).Conclusions: A combination of circulating IL-6 and hFABP level has an additive clinical value for the prediction of stroke outcome.

UR - http://www.scopus.com/inward/record.url?scp=84874936878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874936878&partnerID=8YFLogxK

U2 - 10.1186/cc12564

DO - 10.1186/cc12564

M3 - Article

C2 - 23497639

AN - SCOPUS:84874936878

VL - 17

JO - Critical Care

JF - Critical Care

SN - 1466-609X

IS - 2

M1 - R45

ER -